



**SDI Review Form 1.6**

**PART 1:**

Journal Name:	<a href="#">British Journal of Medicine and Medical Research</a>
Manuscript Number:	<b>MS: 2012 BJMMR 2989</b>
Title of the Manuscript:	<b>Severe Symptomatic Hypocalcemia after Denosumab Administration in an End-Stage Renal Disease Patient on Peritoneal Dialysis with Secondary Hyperparathyroidism – A Different Mechanism for Hungry Bone Syndrome.</b>

**General guideline for Peer Review process is available in this link:**

**(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)**

- This form has total 9 parts. Kindly note that you should use all the parts of this review form.



**SDI Review Form 1.6**

**PART 2: Review Comments**

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b><u>Compulsory</u></b> REVISION comments	<p>The authors should discuss the difficulties in distinguishing different types of bone disease in stage 5 CKD patients (including the use of DEXA in this patient group). These are mentioned in the conclusion but should be discussed too. (Miller Curr Osteoporos Rep 2005 5-12, KDIGO guideline CKD-MBD 2009)</p> <p>Could you comment on the rheumatologists' advice to treat a CKD stage 5 patient with denosumab? Please add discussion on the uncertainty of a beneficial effect on the bones in these patients. (McCornick Am J Kidney Dis 2012 626-628)</p>	
<b><u>Minor</u></b> REVISION comments	Your last sentence on hypercalcaemia should be explained in more detail. Should we be concerned about aggravating tertiary hyperparathyroidism or adynamic bone disease?	
<b><u>Optional/General</u></b> comments		

**Note: Anonymous Reviewer**